New York State Common Retirement Fund Has $3.94 Million Position in Insulet Co. (PODD)
New York State Common Retirement Fund increased its position in shares of Insulet Co. (NASDAQ:PODD) by 14.0% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 71,585 shares of the medical instruments supplier’s stock after buying an additional 8,785 shares during the period. New York State Common Retirement Fund owned 0.12% of Insulet worth $3,943,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Rosenblum Silverman Sutton S F Inc. CA bought a new position in Insulet during the second quarter worth $2,122,000. FMR LLC raised its stake in Insulet by 0.5% during the second quarter. FMR LLC now owns 8,687,487 shares of the medical instruments supplier’s stock worth $445,755,000 after buying an additional 39,836 shares during the last quarter. Northern Trust Corp raised its stake in Insulet by 3.2% during the second quarter. Northern Trust Corp now owns 777,986 shares of the medical instruments supplier’s stock worth $39,919,000 after buying an additional 24,188 shares during the last quarter. Paulson & CO. Inc. bought a new position in Insulet during the second quarter worth $1,283,000. Finally, Fox Run Management L.L.C. bought a new position in Insulet during the third quarter worth $435,000.
Shares of Insulet Co. (NASDAQ:PODD) opened at $68.69 on Thursday. Insulet Co. has a 52 week low of $36.80 and a 52 week high of $72.99. The company has a quick ratio of 4.42, a current ratio of 4.88 and a debt-to-equity ratio of 4.65. The firm has a market cap of $4,030.00, a price-to-earnings ratio of -137.38 and a beta of 1.58.
Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.06. The firm had revenue of $121.80 million during the quarter, compared to the consensus estimate of $114.02 million. Insulet had a negative net margin of 6.66% and a negative return on equity of 43.85%. The business’s revenue was up 28.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.05) earnings per share. equities research analysts predict that Insulet Co. will post -0.43 EPS for the current year.
PODD has been the subject of a number of analyst reports. Barclays lifted their target price on shares of Insulet from $70.00 to $75.00 and gave the stock an “overweight” rating in a research note on Monday, November 20th. Morgan Stanley lifted their target price on shares of Insulet from $55.00 to $63.00 and gave the stock an “equal weight” rating in a research note on Friday, November 3rd. Zacks Investment Research downgraded shares of Insulet from a “hold” rating to a “sell” rating in a research note on Thursday, October 5th. Robert W. Baird set a $65.00 price target on shares of Insulet and gave the company a “buy” rating in a research note on Friday, October 13th. Finally, Wedbush reaffirmed a “buy” rating and issued a $65.00 price target (up from $60.00) on shares of Insulet in a research note on Tuesday, October 10th. Eight research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $61.29.
In other Insulet news, Director James C. Mullen bought 2,500 shares of the firm’s stock in a transaction dated Monday, November 13th. The stock was bought at an average cost of $67.45 per share, with a total value of $168,625.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 2.60% of the company’s stock.
Insulet Company Profile
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODD).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.